168 related articles for article (PubMed ID: 33724800)
1. Ros3 (Lem3p/CDC50) Gene Dosage Is Implicated in Miltefosine Susceptibility in
Espada CR; Albuquerque-Wendt A; Hornillos V; Gluenz E; Coelho AC; Uliana SRB
ACS Infect Dis; 2021 Apr; 7(4):849-858. PubMed ID: 33724800
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the pathways related to intrinsic miltefosine tolerance in Leishmania (Viannia) braziliensis clinical isolates reveals differences in drug uptake.
Espada CR; Magalhães RM; Cruz MC; Machado PR; Schriefer A; Carvalho EM; Hornillos V; Alves JM; Cruz AK; Coelho AC; Uliana SRB
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():139-147. PubMed ID: 30850347
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility to Miltefosine in Brazilian Clinical Isolates of
Espada CR; Ribeiro-Dias F; Dorta ML; Pereira LIA; Carvalho EM; Machado PR; Schriefer A; Yokoyama-Yasunaka JKU; Coelho AC; Uliana SRB
Am J Trop Med Hyg; 2017 Mar; 96(3):656-659. PubMed ID: 28070006
[No Abstract] [Full Text] [Related]
4. Miltefosine-resistant Leishmania infantum strains with an impaired MT/ROS3 transporter complex retain amphotericin B susceptibility.
Mondelaers A; Hendrickx S; Van Bockstal L; Maes L; Caljon G
J Antimicrob Chemother; 2018 Feb; 73(2):392-394. PubMed ID: 29165590
[TBL] [Abstract][Full Text] [Related]
5. Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species.
Obonaga R; Fernández OL; Valderrama L; Rubiano LC; Castro Mdel M; Barrera MC; Gomez MA; Gore Saravia N
Antimicrob Agents Chemother; 2014; 58(1):144-52. PubMed ID: 24145529
[TBL] [Abstract][Full Text] [Related]
6. Effective Genome Editing in
Espada CR; Quilles JC; Albuquerque-Wendt A; Cruz MC; Beneke T; Lorenzon LB; Gluenz E; Cruz AK; Uliana SRB
Front Cell Infect Microbiol; 2021; 11():772311. PubMed ID: 34858879
[TBL] [Abstract][Full Text] [Related]
7. Application of CRISPR/Cas9-Based Reverse Genetics in
Adaui V; Kröber-Boncardo C; Brinker C; Zirpel H; Sellau J; Arévalo J; Dujardin JC; Clos J
Genes (Basel); 2020 Sep; 11(10):. PubMed ID: 33007987
[TBL] [Abstract][Full Text] [Related]
8. Leishmaniasis in the major endemic region of Plurinational State of Bolivia: Species identification, phylogeography and drug susceptibility implications.
Bilbao-Ramos P; Dea-Ayuela MA; Cardenas-Alegría O; Salamanca E; Santalla-Vargas JA; Benito C; Flores N; Bolás-Fernández F
Acta Trop; 2017 Dec; 176():150-161. PubMed ID: 28751163
[TBL] [Abstract][Full Text] [Related]
9. A Luciferase-Expressing Leishmania braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment Outcome.
Coelho AC; Oliveira JC; Espada CR; Reimão JQ; Trinconi CT; Uliana SR
PLoS Negl Trop Dis; 2016 May; 10(5):e0004660. PubMed ID: 27144739
[TBL] [Abstract][Full Text] [Related]
10. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
[TBL] [Abstract][Full Text] [Related]
11. Intraspecies susceptibility of Leishmania (Viannia) braziliensis to antileishmanial drugs: Antimony resistance in human isolates from atypical lesions.
Rugani JN; Quaresma PF; Gontijo CF; Soares RP; Monte-Neto RL
Biomed Pharmacother; 2018 Dec; 108():1170-1180. PubMed ID: 30372818
[TBL] [Abstract][Full Text] [Related]
12. Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug.
Sánchez-Cañete MP; Carvalho L; Pérez-Victoria FJ; Gamarro F; Castanys S
Antimicrob Agents Chemother; 2009 Apr; 53(4):1305-13. PubMed ID: 19188379
[TBL] [Abstract][Full Text] [Related]
13. The antifungal compound butenafine eliminates promastigote and amastigote forms of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis.
Bezerra-Souza A; Yamamoto ES; Laurenti MD; Ribeiro SP; Passero LF
Parasitol Int; 2016 Dec; 65(6 Pt A):702-707. PubMed ID: 27546158
[TBL] [Abstract][Full Text] [Related]
14. The in vitro leishmanicidal activity of hexadecylphosphocholine (miltefosine) against four medically relevant Leishmania species of Brazil.
Morais-Teixeira Ed; Damasceno QS; Galuppo MK; Romanha AJ; Rabello A
Mem Inst Oswaldo Cruz; 2011 Jun; 106(4):475-8. PubMed ID: 21739037
[TBL] [Abstract][Full Text] [Related]
15. Comparative genomic analysis of Leishmania (Viannia) peruviana and Leishmania (Viannia) braziliensis.
Valdivia HO; Reis-Cunha JL; Rodrigues-Luiz GF; Baptista RP; Baldeviano GC; Gerbasi RV; Dobson DE; Pratlong F; Bastien P; Lescano AG; Beverley SM; Bartholomeu DC
BMC Genomics; 2015 Sep; 16(1):715. PubMed ID: 26384787
[TBL] [Abstract][Full Text] [Related]
16. Plasticity of gp63 gene organization in Leishmania (Viannia) braziliensis and Leishmania (Viannia) peruviana.
Victoir K; Dujardin JC; de Doncker S; Barker DC; Arevalo J; Hamers R; Le Ray D
Parasitology; 1995 Sep; 111 ( Pt 3)():265-73. PubMed ID: 7567095
[TBL] [Abstract][Full Text] [Related]
17. Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites.
Pérez-Victoria FJ; Sánchez-Cañete MP; Castanys S; Gamarro F
J Biol Chem; 2006 Aug; 281(33):23766-75. PubMed ID: 16785229
[TBL] [Abstract][Full Text] [Related]
18. Computationally designed synthetic peptides for transporter proteins imparts allostericity in Miltefosine resistant L. major.
Kabra R; Ingale P; Singh S
Biochem J; 2020 May; 477(10):2007-2026. PubMed ID: 32391551
[TBL] [Abstract][Full Text] [Related]
19. 3'Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine.
Carnielli JBT; Dave A; Romano A; Forrester S; de Faria PR; Monti-Rocha R; Costa CHN; Dietze R; Graham IA; Mottram JC
EBioMedicine; 2022 Dec; 86():104378. PubMed ID: 36462405
[TBL] [Abstract][Full Text] [Related]
20. Involvement of nucleoside diphosphate kinase b and elongation factor 2 in Leishmania braziliensis antimony resistance phenotype.
Moreira DS; Murta SM
Parasit Vectors; 2016 Dec; 9(1):641. PubMed ID: 27964761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
